GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.
You may also be interested in...
GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal
Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.
GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal
Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.
Deals Of The Week: GSK/Dynavax, Wyeth Thiakis, Pfizer/Auxilium ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.